Protein tyrosine phosphatase 1B inhibitors for diabetes (original) (raw)

• Zimmet, P., Alberti, K. G. M. M. & Shaw, J. Global and societal implications of the diabetes epidemic. Nature 414, 782–787 (2001).An excellent overview of the epidemiology of diabetes.
  CAS PubMed Google Scholar
• Sinha, R. et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N. Engl. J. Med. 346, 802–810 (2002).
  CAS PubMed Google Scholar
• Rocchini, A. P. Childhood obesity and a diabetes epidemic. N. Engl. J. Med. 346, 854–855 (2002).
  PubMed Google Scholar
• Dunstan, D. W. et al. The rising prevalence of diabetes and impaired glucose tolerance. The Australian diabetes, obesity and lifestyle study. Diabetes Care 25, 829–834 (2002).
  PubMed Google Scholar
• Groop, L. & Orho-Melander, M. The dysmetabolic syndrome. J. Int. Med. 250, 105–120 (2001).
  CAS Google Scholar
• Poitout, V. & Robertson, P. R. Minireview: secondary β-cell failure in type 2 diabetes – a convergence of glucotoxity and lipotoxicity. Endocrinology 143, 339–342 (2002).
  CAS PubMed Google Scholar
• Weyer, C., Tartanni, P. A., Bogardus, C. & Pratley, R. E. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care 24, 89–94 (2001).
  CAS PubMed Google Scholar
• Stumvoll, M., Fritsche, A. & Haring, H. U. Clinical characterization of insulin secretion as the basis for genetic analyses. Diabetes 51 (Suppl. 1), S122–S129 (2002).
  CAS PubMed Google Scholar
• Uusitupa, M. et al. The Finnish Diabetes Prevention Study. Br. J. Nutr. 83 (Suppl. 1), S137–S142 (2000).
  CAS PubMed Google Scholar
• The Diabetes Prevention Study Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393–403 (2002).
• Heine, R. J. & Dekker, J. M. Beyond postprandial hyperglycaemia: metabolic factors associated with cardiovascular disease. Diabetologia 45, 461–475 (2002).
  CAS PubMed Google Scholar
• Marx, J. Unraveling the causes of diabetes. Science 296, 686–689 (2002).
  CAS PubMed Google Scholar
• Saltiel, A. R. & Kahn, C. R. Insulin signaling and the regulation of glucose and lipid metabolism. Nature 414, 799–806 (2001).An excellent overview of metabolic insulin signal transduction.
  CAS PubMed Google Scholar
• Obici, S., Feng, Z., Karkanias, G., Baskin, D. G. & Rossetti, L. Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats. Nature Neurosci. 5, 566–572 (2002).This article shows the role of the insulin receptor at the level of the CNS.
  CAS PubMed Google Scholar
• Saltiel, A. R. & Pessin, J. E. Insulin signaling pathways in time and space. Trends Cell Biol. 12, 65–71 (2002).
  CAS PubMed Google Scholar
• Bryant, N. J., Govers, R. & James, D. E. Regulated transport of the glucose transporter GLUT4. Nature Rev. Mol. Cell Biol. 3, 267–277 (2002).
  CAS Google Scholar
• Smith, U. Impaired ('diabetic') insulin signaling and action occur in fat cells long before glucose intolerance – is insulin resistance initiated in the adipose tissue? Int. J. Obes. Relat. Metab. Disord. 26, 897–904 (2002).
  CAS PubMed Google Scholar
• Ostman, A. & Bohmer, F. D. Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatases. Trends Cell Biol. 11, 258–266 (2001).
  CAS PubMed Google Scholar
• Cheng, A., Dube, N., Gu, F. & Tremblay, M. L. Coordinated action of protein tyrosine phosphatases in insulin signal transduction. Eur. J. Biochem. 269, 1050–1059 (2002).
  CAS PubMed Google Scholar
• Goldstein, B. J., Bittner-Kowalczyk, A., White, M. F. & Harbeck, M. Tyrosine dephosphorylation and deactivation of insulin receptor substrate-1 by protein-tyrosine phosphatase 1B. Possible facilitation by the formation of a ternary complex with the GRB2 adaptor protein. J. Biol. Chem. 275, 4283–4289 (2000).
  CAS PubMed Google Scholar
• Wu, X. et al. Depot-specific variation in protein-tyrosine phosphatase activities in human omental and subcutaneous adipose tissue: a potential contribution to differential insulin sensitivity. J. Clin. Endocrinol. Metab. 86, 5973–5980 (2001).
  CAS PubMed Google Scholar
• Cheung, A. et al. Marked impairment of protein tyrosine phosphatase 1B activity in adipose tissue of obese subjects with and without type 2 diabetes mellitus. J. Lab. Clin. Med. 134, 115–123 (1999).
  CAS PubMed Google Scholar
• Forsell, P. K. A. L., Boie, Y., Montalibet, J., Collins, S. & Kennedy, B. P. Genomic characterization of the human and mouse protein tyrosine phosphatase-1B genes. Gene 260, 145–153 (2000).
  CAS PubMed Google Scholar
• Mok, A. et al. A single nucleotide polymorphism in protein tyrosine phosphatase PTP1B is associated with protection from diabetes or impaired glucose tolerance in Oji–Cree. J. Clin. Endocrinol. Metab. 87, 724–727 (2002).
  CAS PubMed Google Scholar
• Di Paola, R. et al. A variation in 3′UTR of hPTP1B increases specific gene expression and associates with insulin resistance. Am. J. Hum. Genet. 70, 806–812 (2002).
  CAS PubMed PubMed Central Google Scholar
• Echwald, S. M. et al. A P387L variant in protein tyrosine phosphatase-1B (PTP1B) is associated with type 2 diabetes and impaired serine phosphorylation of PTP1B in vitro. Diabetes 51, 1–6 (2002).
  CAS PubMed Google Scholar
• Goldstein, B. J. Protein tyrosine phosphatase 1B (PTP1B): a novel therapeutic target for type 2 diabetes mellitus, obesity and related states of insulin resistance. Curr. Drug Targets Immune Endocr. Metab. Disord. 1, 265–275 (2001).
  CAS Google Scholar
• Ukkola, O. & Santaniemi, M. Protein tyrosine phosphatase 1B: a new target for the treatment of obesity and associated co-morbidities. J. Int. Med. 251, 467–475 (2002).References 27 and 28 review the importance of PTP1B in insulin signalling.
  CAS Google Scholar
• Egawa, K. et al. Protein-tyrosine phosphatase-1B negatively regulates insulin signaling in l6 myocytes and Fao hepatoma cells. J. Biol. Chem. 276, 10207–10211 (2001).
  CAS PubMed Google Scholar
• Chen, H. et al. Protein-tyrosine phosphatases PTP1B and SYP are modulators of insulin-stimulated translocation of GLUT4 in transfected rat adipose cells. J. Biol. Chem. 272, 8026–8031 (1997).
  CAS PubMed Google Scholar
• Venable, C. L. et al. Overexpression of protein-tyrosine phosphatase-1B in adipocytes inhibits insulin-stimulated phosphoinositide 3-kinase activity without altering glucose transport or Akt/Protein kinase B activation. J. Biol. Chem. 275, 18318–18326 (2000).
  CAS PubMed Google Scholar
• Mahadev, K. et al. Hydrogen peroxide generated during cellular insulin stimulation is integral to activation of the distal insulin signaling cascade in 3T3-L1 adipocytes. J. Biol. Chem. 276, 48662–48669 (2001).
  CAS PubMed Google Scholar
• Tao, J., Malbon, C. C. & Wang, H. Insulin stimulates tyrosine phosphorylation and inactivation of protein tyrosine phosphatase 1B in vivo. J. Biol. Chem. 276, 29520–29525 (2001).
  CAS PubMed Google Scholar
• Salmeen, A., Andersen, J. N., Myers, M. P., Tonks, N. K. & Barford, D. Molecular basis for the dephosphorylation of the activation segment of the insulin receptor by protein tyrosine phosphatase 1B. Mol. Cell 7, 615–621 (2001).
  Google Scholar
• Barford, D. The mechanism of protein kinase regulation by protein phosphatases. Biochem. Soc. Trans. 29, 385–391 (2001)
  CAS PubMed Google Scholar
• Xie, L., Zhang, Y. L. & Zhang, Z. Y. Design and characterization of an improved protein tyrosine phosphatase substrate-trapping mutant. Biochemistry 41, 4032–4039 (2002).
  CAS PubMed Google Scholar
• Myers, M. P. et al. TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B. J. Biol. Chem. 276, 47771–47774 (2001).
  CAS PubMed Google Scholar
• Haj, F. G., Verveer, P. J., Squire, A., Neel, B. G. & Bastiaens, P. I. Imaging sites of receptor dephosphorylation by PTP1B on the surface of the endoplasmic reticulum. Science 295, 1708–1711 (2002).
  CAS PubMed Google Scholar
• Gill, G. N. A pit stop at the ER. Science 295, 1654–1655 (2002).Reference 39 is a commentary about reference 38 that brings into perspective how PTP1B might have roles in regulating various RTKs.
  CAS PubMed Google Scholar
• Dadke, S. & Chernoff, J. Interaction of protein tyrosine phosphatase (PTP) 1B with its substrates is influenced by two distinct binding domains. Biochem. J. 364, 377–383 (2002).
  CAS PubMed PubMed Central Google Scholar
• Elchebly, M. et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 283, 1544–1548 (1999).
  CAS PubMed Google Scholar
• Klaman, L. D. et al. Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol. Cell. Biol. 20, 5479–5489 (2000).
  CAS PubMed PubMed Central Google Scholar
• Kaszubska, W. et al. The role of PTP1B in leptin signalling. Keystone Symposia: Diabetes Mellitus: Molecular Mechanisms, Genetics and New Therapies Jan 10–16 226, 81 (2002).PTP1B has been implicated in negatively regulating insulin signal transduction, and this role is extended to include negative regulation of leptin signal transduction.
  Google Scholar
• Zabolotny, J. M. et al. PTP1B regulates leptin signal transduction in vivo. Dev. Cell 2, 489–495 (2002).
  CAS PubMed Google Scholar
• Cook, W. S. & Unger, R. H. Protein tyrosine phosphatase 1B: a potential leptin resistance factor of obesity. Dev. Cell 2, 385–387 (2002).
  CAS PubMed Google Scholar
• Cheng, A. et al. Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B. Dev. Cell 2, 497–503 (2002).
  CAS PubMed Google Scholar
• Zinker, B. A. et al. Reduction of protein tyrosine phosphatase 1B normalizes glucose and improves insulin sensitivity in diabetic mice. Proc. Natl Acad. Sci. USA 99, 11357–11362 (2002).
  CAS PubMed PubMed Central Google Scholar
• Tonks, N. K., Diltz, C. D. & Fischer, E. H. Purification of the major protein-tyrosine phosphatases of human placenta. J. Biol. Chem. 263, 6722–6730 (1988).
  CAS PubMed Google Scholar
• Barford, D., Flint, A. J. & Tonks, N. K. Crystal structure of human protein tyrosine phosphatase 1B. Science 263, 1397–1404 (1994).
  CAS PubMed Google Scholar
• Jia, Z., Barford, D., Flint, A. J. & Tonks, N. K. Structural basis for phosphotyrosine peptide recognition by protein tyrosine phosphatase 1B. Science 268, 1754–1758 (1998).
  Google Scholar
• Groves, M. R., Yao, Z. J., Roller, P. P., Burke, T. R. Jr & Barford, D. Structural basis for inhibition of the protein tyrosine phosphatase 1B by phosphotyrosine peptide mimetics. Biochemistry 37, 17773–17783 (1998).
  CAS PubMed Google Scholar
• Pannifer, A. D. B., Flint, A. J., Tonks, N. K. & Barford, D. Visualization of the cysteinyl-phosphate intermediate of a protein-tyrosine phosphatase by X-ray crystallography. J. Biol. Chem. 273, 10454–10462 (1998).
  CAS PubMed Google Scholar
• Puius, Y. A. et al. Identification of a second aryl phosphate binding site in protein-tyrosine phosphatase 1B: a paradigm for inhibitor design. Proc. Natl Acad. Sci. USA 94, 13420–13425 (1997).
  CAS PubMed PubMed Central Google Scholar
• Hadjuk, P. J., Meadows, R. P. & Fesik, S. W. Discovering high affinity ligands for proteins. Science 278, 497–499 (1997).
  Google Scholar
• Iversen, L. F. et al. Structure based design of a low molecular weight, non-phosphorous, non-peptide, and highly selective inhibitor of protein-tyrosine phosphatase 1B. J. Biol. Chem. 275, 10300–10307 (2000).This paper describes the structure-based design of PTP1B inhibitors.
  CAS PubMed Google Scholar
• Asante-Appiah, E. et al. The YRD motif is a major determinant of substrate and inhibitor specificity in T-cell protein-tyrosine phosphatase. J. Biol. Chem. 276, 26036–26043 (2001).
  CAS PubMed Google Scholar
• Peters, G. H. et al. Residue 259 is a key determinant of substrate specificity of protein-tyrosine phosphatases 1B and α. J. Biol. Chem. 275, 18201–18209 (2000).
  CAS PubMed Google Scholar
• Iversen, L. F. et al. Steric hindrance as a basis for structure-based design of selective inhibitors of protein tyrosine phosphatases. Biochemistry 40, 14812–14820 (2001).
  CAS PubMed Google Scholar
• Iversen, L. F. et al. Structure determination of T cell protein-tyrosine phosphatase. J. Biol. Chem. 277, 19982–19990 (2002).
  CAS PubMed Google Scholar
• Ibarra-Sanchez, M. D. et al. Murine embryonic fibroblasts lacking TC-PTP display delayed G1 phase through defective NF-κB activation. Oncogene 20, 4728–4739 (2001).
  CAS PubMed Google Scholar
• You-Ten, K. E. et al. Impaired bone marrow microenvironment and immune function in T cell protein tyrosine phosphatase-deficient mice. J. Exp. Med. 18, 683–693 (1997).A review of PTP inhibitors from a medicinal chemistry perspective that provides a detailed analysis of the inhibitors identified so far.
  Google Scholar
• Blaskovitch, M. A. & Kim, H.-O. Recent advances in discovery and development of protein tyrosine phosphatase inhibitors. Expert Opin. Ther. Patents 12, 871–905 (2002).
  Google Scholar
• Burke, T. R., Kole, H. K. & Roller, P. P. Potent inhibition of insulin receptor dephosphorylation by a hexamer peptide containing the phosphotyrosyl mimetic F2Pmp. Biochem. Biophys. Res. Commun. 204, 129–134 (1994).
  CAS PubMed Google Scholar
• Burke, T. R. Jr et al. Small molecule interactions with protein-tyrosine phosphatase PTP1B and their use in inhibitor design. Biochemistry 35, 15989–15996 (1996).
  CAS PubMed Google Scholar
• Taing, M. et al. Potent and highly selective inhibitors of the protein tyrosine phosphatase 1B. Biochemistry 38, 3793–3803 (1999).
  CAS PubMed Google Scholar
• Jia, Z. et al. Structure of protein tyrosine phosphatase 1B in complex with inhibitors bearing two phosphotyrosine mimetics. J. Med. Chem. 44, 4584–4594 (2001).
  CAS PubMed Google Scholar
• Bayly, C. & Ohkubo, M. Sulfur substituted aryldifluoromethylphosphonic acids as PTP1B inhibitors. Patent WO 01/70754 (2001).
• Leblanc, Y., Dufresne, C., Gauthier, J. Y. & Young, R. Aromatic phosphonates as protein tyrosine phosphatase 1B (PTP1B) inhibitors. Patent WO 01/46204 (2001).
• Shen, K. et al. Acquisition of a specific and potent PTP1B inhibitor from a novel combinatorial library and screening procedure. J. Biol. Chem. 276, 47311–47319 (2001).
  CAS PubMed Google Scholar
• Leblanc, Y., Dufresne, C., Roy, P. & Wang, Z. Phosphonic and carboxylic acid derivatives as inhibitors of protein tyrosine phosphatase-1B. Patent WO 00/69889 (2000).
• Burke T. R. Jr et al. Enantioselective synthesis of nonphosphorous-containing phosphotyrosyl mimetics and their use in the preparation of tyrosine phophatase inhibitory peptides. Tetrahedron 54, 9981–9994 (1998).
  CAS Google Scholar
• Bleasdale, J. E. et al. Small molecule peptidomimetics containing a novel phosphotyrosine bioisostere inhibit protein tyrosine phosphatase 1B and augment insulin action. Biochemistry 40, 5642–5654 (2001).
  CAS PubMed Google Scholar
• Larsen, S. D. et al. Synthesis and biological activity of a novel class of small molecular weight peptidomimetic competitive inhibitors of protein tyrosine phosphatase 1B. J. Med. Chem. 45, 598–622 (2002).
  CAS PubMed Google Scholar
• Liljebris, C., Larsen, S. D., Ogg, D., Palazuk, B. J. & Bleasedale, J. E. Investigation of potential bioisosteric replacements for the carboxyl groups of peptidomimetic inhibitors of protein tyrosine phosphatase 1B: identification of a tetrazole-containing inhibitor with cellular activity. J. Med. Chem. 45, 1785–1798 (2002).This article describes the production of inhibitors with improved physico-chemical properties.
  CAS PubMed Google Scholar
• Andersen, et al. 2-(Oxalylamino)benzoic acid is a general, competitive inhibitor of protein tyrosine phosphatases. J. Biol. Chem. 275, 7101–7108 (2000).
  CAS PubMed Google Scholar
• Iversen, L. F. et al. Structure based design of a low molecular weight, non-phosphorous, non-peptide, and highly selective inhibitor of protein-tyrosine phosphatase 1B. J. Biol. Chem. 275, 10300–10307 (2000).
  CAS PubMed Google Scholar
• Andersen, H. S. Method of inhibiting protein tyrosine phosphatase 1B and/or T-cell protein tyrosine phosphatase and/or other PTPases with Asp residue at position 48. Patent WO 01/17516 (2001).
• Lui, G. et al. Discovery of competitive, potent, and selective protein tyrosine phosphatase 1B inhibitors. 223rd American Chemical Society National Meeting, Orlando, Florida, April 7–11, 2002 MEDI–002 (2002).
  Google Scholar
• Wrobel, J. et al. PTP1B inhibition and antihyperglycemic activity in the ob/ob mouse model of novel 11-arylbenzo[_b_]naphtha[2,3-_d_]furans and 11-arylbenzo[_b_]naphto[2,3-_d_]thiophenes. J. Med. Chem. 42, 3199–3202 (1999).
  CAS PubMed Google Scholar
• Reuters Business Report. (10 Jun 2002).
• McGovern, S. L., Caselli, E., Grigorieff, N. & Shoichet, B. K. A common mechanism underlying promiscuous inhibitors from virtual and high throughput screening. J. Med. Chem. 45, 1712–1722 (2002).
  CAS PubMed Google Scholar
• Doman, T. N. et al. Molecular docking and high throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. J. Med. Chem. 45, 2213–2221 (2002).The establishment of robust assay systems to determine activity and mechanism.
  CAS PubMed Google Scholar
• Lubben, T., Clampit, J., Stashko, M., Trevillyan, J. & Jirousek, M. R. in Current Protocols in Pharmacology Vol. 8 Ch. 3 (Emma, S. I. et al.) 1–18 (John Wiley, New York, 2001).
  Google Scholar
• Cornish-Bowden, A. Fundamentals of Enzyme Kinetics (Portland Press, London, 1995).
  Google Scholar
• Copeland, R. A. Enzymes: a Practical Introduction to Structure, Mechanism, and Data Analysis 2nd edn (Wiley–VCH, New York, 2000).
  Google Scholar
• Bieth, J. G. Theoretical and practical aspects of proteinase inhibition kinetics. Methods Enzymol. 248, 59–84 (1995).
  CAS PubMed Google Scholar
• Zhang, Y. L., Keng, Y. F., Zhao, Y., Wu, L. & Zhang, Z. Y. Suramin is an active site-directed, reversible, and tight-binding inhibitor of protein-tyrosine phosphatases. J. Biol. Chem. 273, 12281–12287 (1998).
  CAS PubMed Google Scholar
• Lu, B. et al. Enhanced sensitivity of insulin-resistant adipocytes to vanadate is associated oxidative stress and decreased reduction of vanadate (+5) to vanadyl (+4). J. Biol. Chem. 276, 35589–35598 (2001).
  CAS PubMed Google Scholar
• Huyer, G. et al. Mechanism of inhibition of protein-tyrosine phosphatases by vanadate and pervanadate. J. Biol. Chem. 272, 843–851 (1997).
  CAS PubMed Google Scholar
• Crans, D., Bunch, R. L. & Theisen, L. A. Interaction of trace levels of vanadium (IV) and vanadium (V) in biological systems. J. Am. Chem. Soc. 111, 7597–7607 (1989).
  CAS Google Scholar
• Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3–25 (1997).
  CAS Google Scholar
• Palm, K., Stenberg, P., Luthman, K. & Artursson, P. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm. Res. 14, 568–571 (1997).
  CAS PubMed Google Scholar
• Veber, D. F. et al. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45, 2615–2623 (2002).
  CAS PubMed Google Scholar
• Pei, Z. et al. (2_R_)-2-(2′,6′-dichloro-4′-dibenzo(b,d)furan-4″-ylphenoxy)-3-phenylpropanoic acid (A-321842) as a protein tyrosine phosphatase 1B (PTP1B) inhibitor with anti-diabetic effects in ob/ob mice. Diabetes 50 (Suppl. 1), 1524-P (2001).
  Google Scholar
• Burkey, B. F. et al. Pharmacogenomic evaluation of a putative orally active PTP1B inhibitor using ob/ob mice reveals an alternative mechanism of action. Diabetes 51 (Suppl. 2), 138-OR (2002).
  Google Scholar